Status:
TERMINATED
Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study
Lead Sponsor:
Yale University
Conditions:
Liver Transplant; Complications
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus ...
Detailed Description
The research project will take place within each transplant center and can be incorporated into routine pre- and post-transplant care (i.e., no extra visits are needed). Enrolling in this study will e...
Eligibility Criteria
Inclusion
- Recipient
- Adult patients \> or = 18 years of age
- Actively listed for Liver Transplant (LT) or Simultaneous Liver and Kidney (SLK)
- Current HCV NAT- status
- Review by multi-disciplinary transplant team that patient is appropriate for listing for HCV NAT+ liver offers
- Recipient
Exclusion
- Unwilling to consent to post transplant DAA therapy
- Hepatitis B Virus (HBV) viremia
- Donor Inclusion Criteria:
- HCV NAT+
- Deceased Donor organs
- HBV cAb donors will be considered on a case by case basis based on specific recipient factors and plan for post-transplant prophylaxis
- Donor
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 6 2023
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04057001
Start Date
July 1 2019
End Date
March 6 2023
Last Update
August 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale School of Medicine
New Haven, Connecticut, United States, 06510